Toxocara canis meningomyelitis.
Dauriac-Le Masson
Valérie
V
Chochon
Florence
F
Demeret
Sophie
S
Pierrot-Deseilligny
Charles
C
D000328:Adult; D000818:Animals; D000909:Antibodies, Helminth / Q000134:cerebrospinal fluid; D000969:Antinematodal Agents / Q000009:adverse effects / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D004802:Eosinophilia / Q000134:cerebrospinal fluid / Q000469:parasitology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008463:Mebendazole / Q000009:adverse effects / Q000627:therapeutic use; D008581:Meningitis / Q000188:drug therapy / Q000469:parasitology*; D009187:Myelitis / Q000188:drug therapy / Q000469:parasitology*; D011379:Prognosis; D013997:Time Factors; D017166:Toxocara canis; D014120:Toxocariasis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
D000909:Antibodies, Helminth; D000969:Antinematodal Agents; D008463:Mebendazole